RMTI Overview

Board Appointment: Rockwell Medical has appointed Joe Dawson to its board of directors, bringing over 25 years of experience in the renal care and cardiovascular markets, while Andrea Heslin Smiley has resigned to pursue other opportunities.

Expertise and Contributions: Dawson's background includes significant operational experience, contract negotiations, and leadership roles in FDA-regulated markets, which will aid Rockwell Medical in expanding its market share and optimizing manufacturing.

Company Overview: Rockwell Medical specializes in developing and distributing hemodialysis products for dialysis providers, focusing on innovative growth strategies and high-quality customer service to support patients with end-stage kidney disease.

Recognition and Commitment: The company has been recognized as a Great Place to Work for 2023-2025 and aims to deliver life-sustaining dialysis solutions while maintaining a commitment to reliability and customer service.

Q3 Financial Performance: Rockwell Medical reported a non-GAAP EPS of $0.00 and revenue of $15.93 million, a 43.8% decrease year-over-year, missing expectations by $0.31 million.

Adjusted EBITDA and Cash Position: The company recorded an adjusted EBITDA of $50,000 for Q3 2025, a decline from $2.8 million in Q3 2024, but an improvement from a loss of $0.2 million in Q2 2025. Their cash position increased to $23.7 million as of September 30, 2025.

2025 Guidance Reiteration: Rockwell Medical reaffirmed its 2025 guidance, projecting net sales between $65 million and $70 million, with a gross margin of 16% to 18% and adjusted EBITDA ranging from a loss of $0.5 million to a profit of $0.5 million.

Management Changes and Ratings: Heather Hunter has been promoted to COO, and Seeking Alpha has provided a quant rating on Rockwell Medical, alongside historical earnings data.